One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

Respiratory Research

Table 4 Changes from baseline in COPD symptom scores*

	MF-DPI 800 μg QD PM (n = 282)	MF-DPI 400 μg BID (n = 283)	Placebo (n = 263)
Total COPD symptom scores (daytime)
Baseline	2.66	2.78	2.64
Longitudinal average	-0.36	-0.57^†	-0.11
Total COPD symptom scores (nighttime)
Baseline	2.54	2.73	2.65
Longitudinal average	-0.30	-0.50^†	-0.12
Daytime symptom scores
Difficulty Breathing
Baseline	1.06	1.14	0.99
Longitudinal average	-0.11^‡	-0.23^†	0.02
Coughing
Baseline	0.92	0.91	0.97
Longitudinal average	-0.14	-0.16	-0.10
Wheezing
Baseline	0.70	0.74	0.68
Longitudinal average	-0.12	-0.18^†	-0.04
Nighttime Symptom Scores
Difficulty breathing
Baseline	1.00	1.10	1.01
Longitudinal average	-0.10	-0.18^†	0.01
Coughing
Baseline	0.90	0.91	0.96
Longitudinal average	-0.12	-0.16	-0.08
Wheezing
Baseline	0.66	0.73	0.69
Longitudinal average	-0.08	-0.17^†	-0.05

BID = twice daily; COPD = chronic obstructive pulmonary disease; MF-DPI = mometasone furoate administered via a dry powder inhaler.
A P value of 0.025 was the upper limit of statistical significance based on the modified Bonferroni correction used in this analysis.
*This table shows symptom-score results for subjects in whom baseline and post-baseline diary data were available.
^†P ≤ 0.003 vs placebo
^‡P < 0.025 vs placebo

ISSN: 1465-993X